{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:56:38Z","timestamp":1790740598950,"version":"4.1.0"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":6,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018599","name":"Cardinal Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018599","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Outcomes may differ among patients with diffuse large B-cell lymphoma (DLBCL) based on race and ethnicity; however, individuals from diverse racial and ethnic backgrounds have historically been underrepresented in clinical trials. This study describes the real-world characteristics, treatment patterns, and outcomes of patients treated with tafasitamab, an anti-CD19 monoclonal antibody for relapsed or refractory (R\/R) DLBCL, by race and ethnicity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A descriptive subgroup analysis by race and ethnicity was conducted from a retrospective, physician-abstracted medical chart review study. Patients were aged \u226518\u2009years, initiated tafasitamab treatment for R\/R DLBCL on\/after October 21, 2020, and had \u22654\u2009months follow-up; patients who died during follow-up were included. Data were collected from February 22 to March 29, 2023, and from December 18, 2023 to January 31, 2024.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The analysis included 181 patients: 64.1% White, 22.1% Black or African American, 7.7% Other (race other than White, Black or African American, or unknown), 6.1% were of unknown race; 82.3% non-Hispanic, 17.1% Hispanic, and 0.6% were of unknown ethnicity. The median (Q1-Q3) follow-up time for the overall study population from tafasitamab initiation was 14.7 (8.5-17.1) months and was relatively similar for all subgroups. Most patients (71.8%) received tafasitamab in second-line and this was true across subgroups. Real-world overall response rates (95% CI) were 73.3% (65.2-81.3), 82.5% (70.7-94.3), 74.5% (67.5-81.5), and 67.7% (51.3-84.2) for White, Black or African American, non-Hispanic, and Hispanic patients, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Findings suggest effectiveness outcomes among patients receiving tafasitamab for R\/R DLBCL were consistent across racial and ethnic groups.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyag357","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T11:46:16Z","timestamp":1789127176000},"source":"Crossref","is-referenced-by-count":0,"title":["Real-world use of tafasitamab for relapsed or refractory diffuse large B-cell lymphoma among racial and ethnic minorities in the United States"],"prefix":"10.1093","volume":"31","author":[{"given":"Narendranath","family":"Epperla","sequence":"first","affiliation":[{"name":"Division of Hematology, The Ohio State University , Columbus, OH 43201,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loretta J","family":"Nastoupil","sequence":"additional","affiliation":[{"name":"Department of Lymphoma\/Myeloma, The University of Texas MD Anderson Cancer Center , Houston, TX 77030,","place":["United States"]},{"name":"Present address: Southwest Oncology, CommonSpirit Oncology Mercy , Durango, CO 81301,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Feinberg","sequence":"additional","affiliation":[{"name":"Cardinal Health , Dublin, OH 43017,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Galvin","sequence":"additional","affiliation":[{"name":"Incyte Corporation , Wilmington, DE 19803,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8499-3059","authenticated-orcid":false,"given":"Prathamesh","family":"Pathak","sequence":"additional","affiliation":[{"name":"Cardinal Health , Dublin, OH 43017,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa","family":"Amoloja","sequence":"additional","affiliation":[{"name":"Incyte Corporation , Wilmington, DE 19803,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8516-9881","authenticated-orcid":false,"given":"Danielle","family":"Gentile","sequence":"additional","affiliation":[{"name":"Cardinal Health , Dublin, OH 43017,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parisa","family":"Asgarisabet","sequence":"additional","affiliation":[{"name":"Cardinal Health , Dublin, OH 43017,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3421-3755","authenticated-orcid":false,"given":"Kim","family":"Saverno","sequence":"additional","affiliation":[{"name":"Incyte Corporation , Wilmington, DE 19803,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,12]]},"reference":[{"key":"2026092923064479900_oyag357-B1","first-page":"136","article-title":"American Cancer Society\u2019s report on the status of cancer disparities in the United States, 2023","volume":"74","author":"Islami","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"2026092923064479900_oyag357-B2","doi-asserted-by":"crossref","first-page":"7507","DOI":"10.1200\/JCO.2022.40.16_suppl.7507","article-title":"Racial disparities affecting Black patients with diffuse large B-cell lymphoma","volume":"40","author":"Ermann","year":"2022","journal-title":"JCO"},{"key":"2026092923064479900_oyag357-B3","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.clml.2015.06.005","article-title":"Persistent disparities among patients with T-cell non-Hodgkin lymphomas and B-cell diffuse large cell lymphomas over 40 years: a SEER database review","volume":"15","author":"Crozier","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2026092923064479900_oyag357-B4","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.clml.2020.10.003","article-title":"Survival disparities of diffuse large B-cell lymphoma in a community-based inner-city cancer center","volume":"21","author":"Tiu","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2026092923064479900_oyag357-B5","author":"Lymphoma Research Foundation","year":"2025"},{"key":"2026092923064479900_oyag357-B6","author":"National Institutes of Health and National Cancer Institute","year":"2024"},{"key":"2026092923064479900_oyag357-B7","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.clml.2023.01.015","article-title":"Impact of race and age and their interaction on survival outcomes in patients with diffuse large B-cell lymphoma","volume":"23","author":"MacDougall","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2026092923064479900_oyag357-B8","doi-asserted-by":"crossref","first-page":"e18552","DOI":"10.1200\/JCO.2023.41.16_suppl.e18552","article-title":"Racial disparities in DLBCL: analysis of SEER data from 2010-2019","volume":"41","author":"Lee","year":"2023","journal-title":"JCO"},{"key":"2026092923064479900_oyag357-B9","doi-asserted-by":"crossref","first-page":"e858","DOI":"10.1016\/j.clml.2020.06.005","article-title":"Risk factors for cancer-specific mortality and cardiovascular mortality in patients with diffuse large B-cell lymphoma","volume":"20","author":"Zhao","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2026092923064479900_oyag357-B10","author":"U.S. Census Bureau. QuickFacts","year":"2024"},{"key":"2026092923064479900_oyag357-B11","author":"Bristol Myers Squibb","year":"2025"},{"key":"2026092923064479900_oyag357-B12","author":"Kite Pharma","year":"2025"},{"key":"2026092923064479900_oyag357-B13","author":"Novartis","year":"2025"},{"key":"2026092923064479900_oyag357-B14","author":"ADC Therapeutics","year":"2026"},{"key":"2026092923064479900_oyag357-B15","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"key":"2026092923064479900_oyag357-B16","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"2026092923064479900_oyag357-B17","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJMoa2301665","article-title":"Survival with axicabtagene ciloleucel in large B-cell lymphoma","volume":"389","author":"Westin","year":"2023","journal-title":"N Engl J Med"},{"key":"2026092923064479900_oyag357-B18","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"2026092923064479900_oyag357-B19","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S1470-2045(22)00339-4","article-title":"Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study","volume":"23","author":"Sehgal","year":"2022","journal-title":"Lancet Oncol"},{"key":"2026092923064479900_oyag357-B20","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/S1470-2045(21)00139-X","article-title":"Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial","volume":"22","author":"Caimi","year":"2021","journal-title":"Lancet Oncol"},{"key":"2026092923064479900_oyag357-B21","author":"Incyte Corporation","year":"2025"},{"key":"2026092923064479900_oyag357-B22","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/S1470-2045(20)30225-4","article-title":"Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study","volume":"21","author":"Salles","year":"2020","journal-title":"Lancet Oncol"},{"key":"2026092923064479900_oyag357-B23","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1182\/blood.2023021274","article-title":"Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective study","volume":"142","author":"Qualls","year":"2023","journal-title":"Blood"},{"key":"2026092923064479900_oyag357-B24","author":"U.S. Food & Drug Administration","year":"2022"},{"key":"2026092923064479900_oyag357-B25","author":"U.S. Food & Drug Administration","year":"2022"},{"key":"2026092923064479900_oyag357-B26","doi-asserted-by":"crossref","first-page":"e70256","DOI":"10.1002\/jha2.70256","article-title":"A real-world study of tafasitamab for the treatment of relapsed or refractory diffuse large B-cell lymphoma in the United States","volume":"7","author":"Saverno","year":"2026","journal-title":"EJHaem"},{"key":"2026092923064479900_oyag357-B27","first-page":"100252","article-title":"Race\/ethnicity reporting and representation in US clinical trials: a cohort study","volume":"11","author":"Turner","year":"2022","journal-title":"Lancet Reg Health Am"},{"key":"2026092923064479900_oyag357-B28","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/jnci\/djaa155","article-title":"\u201cWhen offered to participate\u201d: a systematic review and meta-analysis of patient agreement to participate in cancer clinical trials","volume":"113","author":"Unger","year":"2021","journal-title":"J Natl Cancer Inst"},{"key":"2026092923064479900_oyag357-B29","doi-asserted-by":"crossref","first-page":"3860","DOI":"10.1002\/cncr.34454","article-title":"Interventions to increase racial and ethnic minority accrual into cancer clinical trials: a systematic review","volume":"128","author":"Nouvini","year":"2022","journal-title":"Cancer"},{"key":"2026092923064479900_oyag357-B30","author":"U.S. Food & Drug Administration","year":"2024"},{"key":"2026092923064479900_oyag357-B31","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.3324\/haematol.2020.275958","article-title":"Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma","volume":"106","author":"Duell","year":"2021","journal-title":"Haematologica"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag357\/71088122\/oyag357.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/10\/oyag357\/71088122\/oyag357.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/10\/oyag357\/71088122\/oyag357.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:06:54Z","timestamp":1790737614000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag357\/8795920"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,9]]},"references-count":31,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,9,9]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag357","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,9,9]]},"article-number":"oyag357"}}